Aim： To investigate the activity of RRR-α-tocopheryloxybutyric acid （TOB）, an ether analog of RRR-α-tocopheryl succinate （VES）, in prostate cancer cells. Methods： VES and TOB were used to treat prostate cancer...Aim： To investigate the activity of RRR-α-tocopheryloxybutyric acid （TOB）, an ether analog of RRR-α-tocopheryl succinate （VES）, in prostate cancer cells. Methods： VES and TOB were used to treat prostate cancer LNCaP, PC3, and 22Rvl cells and primary-cultured prostate fibroblasts. The proliferation rates were determined by MTT assay, the cell viabilities were determined by trypan blue exclusion assay, and the cell deaths were evaluated by using Cell Death Detection ELISA kit. The protein expression levels were determined by Western blot analysis. Results： The MTT growth assay demonstrated that TOB could effectively suppress the proliferation of prostate cancer cells, but not normal prostate fibroblasts. Mechanism dissections revealed that TOB reduced cell viability and induced apoptosis in prostate cancer cells similar to VES. In addition, both TOB and VES suppressed prostate-specific antigen （PSA） at the transcriptional level leading to reduced PSA protein expression. Furthermore, vitamin D receptor （VDR） expression increased after the addition of TOB. Conclusion： Our data suggests that the VES derivative, TOB, is effective in inhibiting prostate cancer cell proliferation, suggesting that TOB could be used for both chemopreventive and chemotherapeutic purposes in the future.展开更多
目的为评价CEREC椅旁CAD/CAM系统制作的IPS e.max CAD玻璃陶瓷高嵌体应用于根管治疗后牙缺损病例的临床效果。方法选择42例根管治疗后牙,应用高嵌体的牙体预备方式,采用CEREC椅旁CAD/CAM修复系统和IPS e.max CAD玻璃陶瓷,即刻完成修复...目的为评价CEREC椅旁CAD/CAM系统制作的IPS e.max CAD玻璃陶瓷高嵌体应用于根管治疗后牙缺损病例的临床效果。方法选择42例根管治疗后牙,应用高嵌体的牙体预备方式,采用CEREC椅旁CAD/CAM修复系统和IPS e.max CAD玻璃陶瓷,即刻完成修复体并粘接;修复1年后复查,参照改良修正后的美国公众健康服务标准(US Public Health Service Criteria,USPHS),在修复体边缘染色、边缘继发龋、修复体边缘适合性、修复体崩瓷折裂或脱落、修复体颜色、牙龈健康状况、修复体邻接关系、患者满意度8个方面进行评价。结果修复体边缘染色C级病例1例,成功率97.6%;边缘继发龋C级病例1例,成功率97.6%;修复体邻接关系欠佳C级病例1例,成功率97.6%;在边缘适合性、修复体崩瓷折裂或脱落、修复体颜色、牙龈健康状况、患者满意方面表现优秀,成功率均为100%。结论椅旁CAD/CAM系统制作的IPS e.maxCAD高嵌体修复体在短期内可取得良好的修复效果。展开更多
文摘Aim： To investigate the activity of RRR-α-tocopheryloxybutyric acid （TOB）, an ether analog of RRR-α-tocopheryl succinate （VES）, in prostate cancer cells. Methods： VES and TOB were used to treat prostate cancer LNCaP, PC3, and 22Rvl cells and primary-cultured prostate fibroblasts. The proliferation rates were determined by MTT assay, the cell viabilities were determined by trypan blue exclusion assay, and the cell deaths were evaluated by using Cell Death Detection ELISA kit. The protein expression levels were determined by Western blot analysis. Results： The MTT growth assay demonstrated that TOB could effectively suppress the proliferation of prostate cancer cells, but not normal prostate fibroblasts. Mechanism dissections revealed that TOB reduced cell viability and induced apoptosis in prostate cancer cells similar to VES. In addition, both TOB and VES suppressed prostate-specific antigen （PSA） at the transcriptional level leading to reduced PSA protein expression. Furthermore, vitamin D receptor （VDR） expression increased after the addition of TOB. Conclusion： Our data suggests that the VES derivative, TOB, is effective in inhibiting prostate cancer cell proliferation, suggesting that TOB could be used for both chemopreventive and chemotherapeutic purposes in the future.
文摘目的为评价CEREC椅旁CAD/CAM系统制作的IPS e.max CAD玻璃陶瓷高嵌体应用于根管治疗后牙缺损病例的临床效果。方法选择42例根管治疗后牙,应用高嵌体的牙体预备方式,采用CEREC椅旁CAD/CAM修复系统和IPS e.max CAD玻璃陶瓷,即刻完成修复体并粘接;修复1年后复查,参照改良修正后的美国公众健康服务标准(US Public Health Service Criteria,USPHS),在修复体边缘染色、边缘继发龋、修复体边缘适合性、修复体崩瓷折裂或脱落、修复体颜色、牙龈健康状况、修复体邻接关系、患者满意度8个方面进行评价。结果修复体边缘染色C级病例1例,成功率97.6%;边缘继发龋C级病例1例,成功率97.6%;修复体邻接关系欠佳C级病例1例,成功率97.6%;在边缘适合性、修复体崩瓷折裂或脱落、修复体颜色、牙龈健康状况、患者满意方面表现优秀,成功率均为100%。结论椅旁CAD/CAM系统制作的IPS e.maxCAD高嵌体修复体在短期内可取得良好的修复效果。
